GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer
Open Access
- 6 September 2024
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-9
Abstract
GATA binding protein 3 (GATA3) is essential for normal development of the mammary gland and associated with ER-positive breast cancer. Loss of GATA3 has been associated with epithelial-mesenchymal transition (EMT) in experimental studies. We investigated tumoral GATA3 in a cohort of postmenopausal patients with lymph-node negative breast cancer, randomized to adjuvant tamoxifen or control. Nuclear GATA3 expression was assessed with immunohistochemistry and GATA3 gene expression with Agilent microarrays. High GATA3 nuclear expression was associated with a lower rate of distant recurrence in ER-positive breast cancer (HR = 0.60, 95% CI 0.39–0.93). Low gene expression of GATA3 was associated with limited long-term benefit from adjuvant tamoxifen (interaction: p = 0.033). GATA3 gene expression was associated with the epithelial markers CDH1 (E-cadherin) and FOXA1, whereas negatively associated with several mesenchymal markers. Low expression of CDH1 was associated with marginal tamoxifen benefit (HR = 0.80 (0.43–1.49)), whereas patients with higher expression showed a significant benefit (HR = 0.33 (0.20–0.55), interaction: p = 0.029). In ER-positive breast cancer, diminished expression of GATA3 is associated with markers of EMT and poor long-term benefit from tamoxifen.Keywords
This publication has 41 references indexed in Scilit:
- Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen TherapyJAMA Network Open, 2021
- Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 DecadesJAMA Oncology, 2017
- GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent diseaseCancer Letters, 2016
- Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer MetastasisCancer Cell, 2015
- Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefitBreast Cancer Research and Treatment, 2012
- Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifenBreast Cancer Research and Treatment, 2010
- PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancerBreast Cancer Research and Treatment, 2010
- GATA3 in development and cancer differentiation: Cells GATA have it!Journal of Cellular Physiology, 2009
- GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer ModelCancer Cell, 2008
- Post-translational modifications of steroid receptorsBiomedicine & Pharmacotherapy, 2006